For research use only. Not for therapeutic Use.
BRD3308（Cat No.:I016437）is a potent and selective inhibitor of HDAC3 (Histone Deacetylase 3), with IC50 values of 54nM, 1.26μM, and 1.34μM for HDAC3, HDAC1, and HDAC2, respectively. It exhibits the ability to activate HIV-1 transcription. Additionally, BRD3308 effectively prevents pancreatic β-cell apoptosis induced by inflammatory cytokines, specifically under conditions of glucolipidotoxic stress. Furthermore, it enhances the functional release of insulin. These findings suggest that BRD3308 holds promise as a therapeutic agent for conditions involving impaired β-cell function and insulin secretion.
| Catalog Number | I016437 |
| CAS Number | 1550053-02-5 |
| Molecular Formula | C₁₅H₁₄FN₃O₂ |
| Purity | ≥95% |
| IUPAC Name | 4-acetamido-N-(2-amino-4-fluorophenyl)benzamide |
| InChI | InChI=1S/C15H14FN3O2/c1-9(20)18-12-5-2-10(3-6-12)15(21)19-14-7-4-11(16)8-13(14)17/h2-8H,17H2,1H3,(H,18,20)(H,19,21) |
| InChIKey | RRJDFENBXIEAPD-UHFFFAOYSA-N |
| SMILES | CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)F)N |
| Reference | [1]. Barton KM, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014 Aug 19;9(8):e102684.<br>[2]. Lundh M, et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015 Jul;17(7):703-7.<br>[3]. Wagner FF, et al. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chem Biol. 2016 Feb 19;11(2):363-74. |
